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Abstract
Background: Embryonated chicken eggs have been used since the mid-20th century to grow a
wide range of animal viruses to high titers. However, eggs have found so far only limited use in the
production of recombinant proteins. We now describe a system, based on a Sendai virus
minigenome, to produce large amounts of heterologous viral glycoproteins in the allantoic cavity
of embryonated eggs.
Results: Soluble forms of human respiratory syncytial virus (HRSV) and human metapneumovirus
(HMPV) fusion (F) proteins, devoid of their transmembrane and cytoplasmic domains, were
produced in allantoic fluids using the Sendai minigenome system. The first step was rescuing in cell
cultures Sendai virus minigenomes encoding the proteins of interest, with the help of wild type
Sendai virus. The second step was propagating such recombinant defective viruses, together with
the helper virus, in the allantoic cavity of chicken embryonated eggs, and passage to optimize
protein production. When compared with the production of the same proteins in the culture
supernatant of cells infected with vaccinia recombinants, the yield in the allantoic fluid was 5–10
fold higher. Mutant forms of these soluble proteins were easily constructed by site-directed
mutagenesis and expressed in eggs using the same approach.
Conclusion: The simplicity and economy of the Sendai minigenome system, together with the high
yield achieved in the allantoic fluid of eggs, makes it an attractive method to express soluble
glycoproteins aimed for structural studies.
Background
Over the past decades different expression systems have
been developed for production of recombinant proteins.
Each of these systems has strengths and weaknesses con-
cerning yield, cost, speed, ease of manipulation and fold-
ing and post-translational modifications of the target
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proteins.  E. coli is the simplest and most widely used
organism for protein expression due to low cost and ease
of use but it has serious limitations for expression of
mammalian gene products, particularly glycoproteins [1].
Unmodified yeasts, as eukaryotes, are suitable for the pro-
duction of proteins that do not require mammalian-type
glycosylation [2]. However, cultured animal cells still
remain the best system in which to produce mammalian
glycoproteins, although they have complex nutritional
requirements and are sensitive to viral and bacterial con-
tamination [1].
A repertoire of animal viruses has been grown in embryo-
nated chicken eggs since the early 1930's [3]. Eggs have
also been used for large-scale production of viruses, aimed
at obtaining purified proteins suitable for vaccines or for
structural studies [4]. For example, the influenza haemag-
glutinin [5] (HA) and neuraminidase [6] (NA) ectodo-
mains obtained after protease digestion of egg-grown
virus have been crystallized and their structures solved by
X-ray diffraction analysis. Chicken eggs have the appeal-
ing properties of low cost and ease of manipulation for
large-scale production of viruses and recombinant pro-
teins.
Since Sendai virus (SeV, a member of the Paramyxoviridae
family within the Mononegavirales order) replicates very
efficiently in eggs, we contemplated the possibility of
using this virus as a vector for large-scale production of
heterologous glycoproteins in the allantoic fluid of
embryonated eggs. Rescue of recombinant SeV [7] and
other mononegavirales from cDNA copies of their respec-
tive negative single-stranded RNA genomes has been
achieved, as well as expression of foreign proteins from
the recombinant viruses [8]. However, cDNA cloning and
rescue of recombinant paramyxoviruses still entails labo-
rious and time-consuming steps. These difficulties are cir-
cumvented in rescuing replication defective
minigenomes. These are short negative-stranded RNA
molecules in which most of the internal coding sequences
of the viral genome have been replaced by a reporter gene
(or any other heterologous sequence). Paramyxovirus
minigenomes obtained by cDNA cloning can be ampli-
fied in transfected cells either expressing a minimal set of
complementing viral proteins or superinfected with a wild
type homologous helper virus. Although the minigenome
can then be amplified in tissue culture, SeV replication is
much more efficient in eggs than in cultured cells. There-
fore, a SeV minigenome seemed an attractive and versatile
vector for the expression of foreign proteins in chicken
eggs.
Two heterologous proteins were chosen for proof-of-prin-
ciple experiments: i) a membrane-anchorless form of the
human respiratory syncytial virus (HRSV) fusion (F) glyc-
oprotein [9] and ii) a similar anchorless F protein of the
recently identified human metapneumovirus [10]
(HMPV). Both, HRSV F and HMPV F are structural pro-
teins that are synthesized as inactive F0 precursors that
need to be cleaved proteolytically before becoming mem-
brane-fusion competent. Whereas HRSV F0 is cleaved
twice at sites I and II containing furin recognition
sequences [11], HMPV F0 is cleaved only once after a sin-
gle Arg residue [12]. Both proteins are trimers in which
each monomer is made of the two chains (F1 and F2) gen-
erated after precursor cleavage. A membrane-anchorless
HRSV F protein that lacks the C-terminal 50 amino acids
(FTM-), including the transmembrane and cytoplasmic
regions, has been expressed in HEp-2 cells infected with a
recombinant vaccinia virus [9] (rVV). HRSV/FTM- folds
into trimers that are seen under the electron microscope as
cone-shaped molecules [13]. An analogous rVV express-
ing an anchorless form of HMPV/F protein has been made
(described in Methods).
Results and Discussion
The previously described HA-M-Svec-36-CB119 plasmid
[14] (here renamed SVec/HA-M) carries a cDNA SeV mini-
genome, which encodes an HA tagged SeV matrix protein
(HA-M), flanked by a T7 RNA polymerase promoter and
the hepatitis delta virus genomic ribozyme (Figure 1A).
Transcription of SVec/HA-M by the T7 polymerase results
in a positive polarity RNA that, after ribozyme self-cleav-
age, contains at both ends SeV sequences required for rep-
lication and transcription by the SeV polymerase.
Therefore, expression of the HA-M protein can be
achieved by transfecting BSR-T7/5 cells [15] (which
express constitutively the T7 polymerase) with SVec/HA-
M and three other plasmids encoding, also under a T7
promoter, the following set of complementing proteins: i)
the viral RNA-dependent RNA polymerase encoded by the
SeV L gene, ii) the phosphoprotein (P), a cofactor of the
viral polymerase and iii) the nucleoprotein (N), a major
structural protein that binds tightly to both SeV genome
and anti-genome (a replication intermediate of positive
polarity), protecting them from RNase degradation.
The HA-M sequence was replaced in the SVec/HA-M plas-
mid by sequences encoding the FTM- forms of either HRSV
F or HMPV F proteins (Figure 1A). Cloning was designed
to follow the "rule of six" (i.e. that the number of nucle-
otides in the transcribed minigenome is a multiple of six),
a restriction imposed by the number of nucleotides inter-
acting with each N protein monomer in the SeV ribonu-
cleoprotein complex [16]. Then, BRS-T7/5 cells were
transfected with SVec plasmids encoding HA-M, HRSV/
FTM- or HMPV/FTM- and the set of support plasmids.
Expression of the minigenome-encoded products in trans-
fected cells was confirmed by immunofluorescence of par-
allel cultures with specific antibodies (Figure 1B). TwentyBMC Biotechnology 2007, 7:17 http://www.biomedcentral.com/1472-6750/7/17
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four hours after transfection, the cells were infected with
SeV that provided the required viral products for incorpo-
ration of the minigenome ribonucleoproteins into virus
particles that would be found, together with wild type SeV
particles, in the supernatants of transfected/infected BSR-
T7/5 cells, constituting now a mixed virus stock; i.e. virus
particles harboring minigenomes or full-length genomes.
The mixed SeV stocks collected 24 hours after SeV infec-
tion of BSR-T7/5 cells were inoculated into 9-day-old
embryonated chicken eggs for replication within cells of
the choriallantoic membrane. Amplification of the SeV
minigenome after each passage was evaluated indirectly
by Western blot of each recombinant protein. In parallel,
multiplication of wild type SeV was evaluated by Western
blot of the allantoic fluid with a monoclonal antibody
(Mab) specific for the SeV F protein. The amount of allan-
toic fluid in the Western blots was standardized with an
antibody specific for egg albumin (Figure 1C). In general,
a major band of the Sendai virus F protein was detected
SeV minigenome expression system Figure 1
SeV minigenome expression system. (A) BSR-T7/5 cells were co-transfected with a minigenome plasmid (SVec/HA-M, 
SVec/HRSV/FTM-, or SVec/HMPV/FTM-) and plasmids encoding for SeV L, N, and P proteins, and infected 24 h later with SeV at 
a m.o.i. of 5. Cells were harvested 24 h.p.i. and 200 μl of culture supernatant were inoculated into 9-day-old embryonated 
chicken eggs, which were incubated for 48 h at 34°C, and then transferred to 4°C overnight. Allantoic fluid was harvested and 
subjected to consecutive passages. (B) The immunofluorescence assay was performed in parallel cultures of BSR-T7/5 cells 
growing in microchamber slides. Cells were transfected with the indicated minigenome along with support plasmids (upper 
panels) or with the minigenome plasmid only (lower panels) and fixed and stained 48 hours later. (C) Western blot of allantoic 
fluid from passages 1–7 (lanes 1–7) are compared with allantoic fluid from uninfected eggs (0). Upper panels were developed 
with antibodies specific for each of the target proteins (HA-M, HRSV/FTM-, or HMPV/FTM-), middle panels show expression lev-
els of SeV F protein, and lower panels show chicken egg albumin (ova) expression levels, used to standardize the amount of 
protein loaded in each lane. The asterisk (*) denotes bands that cross-reacted with certain antibodies whose identity has not 
been investigated. F0 and F1 denote uncleaved F protein precursor and F1 chain, respectively. T7 indicates the bacteriophage 
T7 promoter and Rz is the hepatitis delta virus ribozyme.BMC Biotechnology 2007, 7:17 http://www.biomedcentral.com/1472-6750/7/17
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after the first passage in eggs, whereas protein bands of the
recombinant proteins were detected only after 2–3 pas-
sages. A cycling expression pattern was observed thereaf-
ter. Maximal levels of HA-M, HRSV/FTM- or HMPV/FTM-
proteins in allantoic fluids correlated with low expression
levels of SeV F protein and vice versa (Figure 1C). This is
likely to reflect the competition between minigenomes
and full-length SeV genomes for replication and incorpo-
ration into virus particles. Minigenomes being shorter are
expected to replicate more rapidly than full-length viral
genomes. Consequently, minigenomes should quickly
outnumber full-length genomes in the infected cells and
in the virus particles produced. However, since minige-
nome amplification and packaging requires helper virus
functions, excess minigenome will result in a decrease in
minigenome accumulation in the virus stock.
Whereas essentially all the HRSV/FTM- was proteolitically
processed to the F1 and F2 chains (only F1 was observed
with the antibody used in the Western blot) about 50% of
the HMPV/FTM- precursor remained unprocessed as F0
(Figure 1C). This different behavior is likely to reflect the
different proteolytic processing pathways of HRSV and
HMPV F0 precursors mentioned above. The SeV F protein
was processed efficiently to generate the F1 chain detected
with antibody GB5.
The Western blots of Figure 2A show that the recombinant
FTM- glycoproteins produced in eggs, in contrast to SeV
HA-M, remained essentially unassociated with SeV parti-
cles. Thus, after sedimentation of virions from the allan-
toic fluid, HA-M was found exclusively in the pellet
fraction, in agreement with previous demonstration that
this molecule can replace the matrix protein of helper SeV
in mature particles [17]. In contrast, HRSV/FTM- and
HMPV/FTM- were found mainly, in their respective super-
natants. The small amount of HRSV/FTM- found in the pel-
let was probably due to aggregates, generated after
complete cleavage of monomers in the protein trimer
[11], that may have co-sedimented with SeV particles.
Figure 2B shows comparative Western blots of rVV-
infected cell supernatants and allantoic fluids containing
either HRSV/FTM- or HMPV/FTM- glycoproteins. Densito-
metric quantifications estimated that the concentrations
of FTM- proteins in the allantoic fluids were 5–10-fold
higher than in the cell supernatants. Considering that one
egg yields 5–10 ml of allantoic fluid, the amount of FTM-
protein produced in one egg is equivalent to that found in
the supernatant of rVV-infected cells grown as monolayer
in a plastic flask of 175 cm2 (~108 cells). This yield reduces
the production cost of FTM- proteins about 10 times, con-
sidering only the cost of plastic and medium for growing
animal cells in comparison with the cost of eggs. How-
ever, other significant advantages of embryonated eggs
are: i) shorter incubation times, ii) simplicity of manipu-
lations and iii) inexpensive equipment needed for pro-
duction. These considerations are applicable at the
laboratory scale, but other cost calculations may need to
be done for industrial processes that require different
manipulations and equipment.
As mentioned previously, the small size of plasmids con-
taining cDNA copies of SeV minigenomes facilitates
genetic manipulation of the encoded foreign gene. FTM-
mutants could be easily obtained by site-directed muta-
genesis of the minigenomes. As an example, Figure 3A
shows the Western blot of a HRSV/FTM- mutant (lane 2),
compared to FTM- wild type (lane 1), in which the basic
amino acids of the two furin sites were replaced by Asn
residues (NN mutant). Expression of this mutant in eggs
generated an anchorless F protein in which all monomers
remained uncleaved (F0), as shown previously for an
equivalent mutant expressed from rVV [18]. Inhibition of
FTM- cleavage may be important to maintain this soluble
protein unaggregated since, as reported previously, exten-
sive cleavage of its monomers leads to formation of aggre-
gates [11] that sedimented with SeV particles as seen in
Figure 2A.
The HRSV/FTM- protein produced in eggs has been found
indistinguishable in a variety of tests (including reactivity
with a panel of MAbs) from that produced in cells infected
with rVV. As an example, the NN mutant has been puri-
fied to homogeneity (Figure 3B) following the same puri-
fication scheme used previously for purification of FTM-
from the supernatant of rVV-infected cells [11,19]. Elec-
tron microscopy of the purified FTM- NN protein after neg-
ative staining revealed the presence of unaggregated cone-
shaped molecules (Figure 3C) similar to those observed in
preparations of the same protein from rVV-infected cells
(Figure 3D).
Mononegavirales minigenomes expressing foreign
reporter genes have been used extensively to dissect cis-
acting sequences, including promoters, transcription sig-
nals and RNA editing signals, as well as trans-acting factors
required for replication and/or transcription [8]. This
report adds to this list the use of mononegaviral (SeV)
minigenomes for high yield production of recombinant
soluble proteins in chicken eggs. Although only soluble
viral glycoproteins have been tested in this paper, there is
no reason to believe that the system could not be used for
the expression of non-viral glycoproteins, since the
expressed molecules were not incorporated into virus par-
ticles (as seen in Figure 2A) but were simply secreted to
the allantoic fluid.
Coronavirus minigenomes have been used for expression
of heterologous proteins in piglets [20] and activeBMC Biotechnology 2007, 7:17 http://www.biomedcentral.com/1472-6750/7/17
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gamma-interferon in embryonated chicken eggs [21],
although estimation of the amount of foreign protein
being expressed was not reported. However, instability of
the heterologous gene in the coronavirus minigenome
after 4–5 passages in tissue culture cells [20] may be an
important limitation for its use in the systematic produc-
tion of recombinant proteins. In contrast, production of
the foreign proteins by the SeV minigenomes reported
here was maintained at least after 14 passages in eggs (not
shown), although following the cycling pattern depicted
in Figure 1C. Nevertheless, high constant production of
FTM- proteins was achieved by preparing large stocks of
passage 3 that were then used to inoculate repetitively
eggs for protein purification from passage 4 (see Figure
1C).
Production of active human monoclonal antibodies [22]
and single-chain antibodies [23] has been achieved in
eggs of chimeric hens. Expression levels were very high,
although the recombinant proteins were found in the egg
white that has a high ovalbumin concentration. Whereas
chimeric chickens may be useful bioreactors for expres-
sion of pharmaceutical molecules [24,25], the intense
labor- and time-consuming steps involved in obtaining
the transgenic chickens limits the system versatility. In
contrast, manipulation of the SeV minigenome involves
very simple steps that facilitate incorporation of foreign
genes and generation of mutant heterologous proteins for
comparative studies. Expression of these recombinant
proteins in the allantoic fluid, that has a limited number
of chicken derived molecules, also facilitates the purifica-
tion steps of the target proteins.
Conclusion
The SeV minigenome system described here represents a
low-cost, simple and versatile approach for large-scale
production of recombinant soluble glycoproteins in the
allantoic fluid of chicken eggs.
Methods
Cells and Viruses
Hep-2 and CV-1 cells were grown in DMEM medium con-
taining Penicillin and Streptomycin (100 U/ml and 100
μg/ml, respectively) (Cambrex), supplemented with 10%
fetal calf serum (DMEM10) (Linus) at 37°C in a 5% CO2
atmosphere. BSR-T7/5 cells (a BHK-derived cell line that
constitutively expresses the T7 RNA polymerase, a kind
gift of K-K. Conzelmann, Munich, Germany) were grown
in DMEM10, and G-418 (1 mg/ml) was added every third
passage [15] to ensure expression of the T7 polymerase.
Wild type Sendai virus (SeV), strain Z, was propagated in
embryonated 9-day-old chicken eggs, as described [26].
Recombinant vaccinia virus (rVV) expressing a soluble
form of the HRSV F glycoprotein (FTM-), lacking the trans-
membrane and cytoplasmic domains, has been described
[9]. An analogous rVV expressing HMPV/FTM- was
obtained using the procedure of Blasco and Moss [27].
Briefly, the gene encoding HMPV F was amplified by RT-
PCR from total RNA extracted from HMPV infected cells
Analysis of soluble proteins in allantoic fluids Figure 2
Analysis of soluble proteins in allantoic fluids. (A) Allantoic fluids (4.5 ml) from eggs inoculated with mixed stocks of SeV 
and SeV minigenomes expressing HA-M, HRSV/FTM- or HMPV/FTM- were centrifuged through a 25% glycerol cushion. Pellets 
were resuspended in 100 μl of PBS. All fractions were analyzed by Western blot. Five microliters of allantoic fluid from unin-
fected eggs (0) were compared with 5 μl of allantoic fluid from eggs inoculated with virus stocks encoding the indicated pro-
teins (1), 5 μl of resuspended pellet (2), and 15 μl of the ultracentrifugation supernatant (3). (B) Comparison by Western blot 
of the expression levels of HRSV/FTM-and HMPV/FTM- from allantoic fluid or the supernatant of rVV-infected cells. Twenty 
microliters of culture supernatant from mock-infected HEp-2 cells (1), and 5, 10, or 20 μl of supernatant from rVV-infected 
cells (2, 3 and 4, respectively) were compared with 20 μl of uninfected allantoic fluid (5) and 5, 10, or 20 μl of allantoic fluid 
harvested from passage 4 (see Figure 1C) of defective SeV virus-inoculated embryonated eggs (6, 7 and 8, respectively). Aster-
isk (*) denotes a rVV band that cross-reacts with anti-F specific reagents.BMC Biotechnology 2007, 7:17 http://www.biomedcentral.com/1472-6750/7/17
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(strain NL/01/99, a kind gift of A.D.M.E. Osterhaus, Rot-
terdam, The Netherlands) with specific primers and
cloned into the pRB21 plasmid [27]. The plasmid pRB21/
HMPV/FTM- was engineered by substituting the amino
acid G489 of the F protein by a stop codon. CV-1 monol-
ayers were infected with the vaccinia virus vRB12 [27] and
subsequently transfected with the plasmid pRB21/HMPV/
FTM-. vRB12 lacks most of the gene encoding vp37, the
major protein component of the vaccinia virus envelope,
and as a result is unable to form extracellular enveloped
virions. Hence, vRB12 is defective in plaque formation
under standard conditions. pRB21-derived plasmids carry
a complete copy of vp37 and thus, via homologous
recombination with vRB12, restore VP37 function. rVV-
HMPV/FTM- was obtained from the supernatant of
infected/transfected CV-1 cells and subjected to three con-
secutive rounds of plaque purification, and a virus stock
was grown in this cell line.
Plasmids
The plasmid HA-M-SVec-36-CB119 (here SVec/HA-M)
contains a SeV-defective RNA genome cloned under the
control of the T7 RNA polymerase promoter, and includes
the SeV matrix protein gene tagged with the influenza
Purification of HRSV/FTM-NN from allantoic fluid Figure 3
Purification of HRSV/FTM-NN from allantoic fluid. (A) Allantoic fluid (10 μl) from passage 4 of defective SeV expressing 
HRSV/FTM- (1) compared by Western Blot with passage 4 of HRSV/FTM-NN (2). (B)Coomasie-stained SDS-PAGE of allantoic 
fluid from uninfected eggs (1) compared to allantoic fluid from SVec/HRSV/FTM- NN infected eggs (2), HRSV/FTM- NN after 
concentration and affinity chromatography (3), and after a last purification step by gel filtration (4). (C) Electron Microscopy of 
HRSV/FTM- NN purified from eggs or (D) from rVV infected cell supernatant. The bar denotes 50 nm.BMC Biotechnology 2007, 7:17 http://www.biomedcentral.com/1472-6750/7/17
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virus haemagglutinin protein epitope [14] (HA-M). Plas-
mids SVec/HRSV/FTM- and SVec/HMPV/FTM-, were
obtained by replacing the HA-M gene in the vector SVec/
HA-M by HRSV/FTM- and HMPV/FTM-. Briefly, HRSV/FTM-
and HMPV/FTM- were PCR amplified with primers con-
taining XmaI and EcoRI sites, and subcloned in XmaI-
EcoRI digested SVec/HA-M. Sequencing of the plasmids
confirmed the compliance of the "rule of six" [16]. Plas-
mids encoding the RNA dependent RNA polymerase (L),
the nucleoprotein (N) and the phosphoprotein (P) of SeV
under the control of a T7 polymerase promoter (pGEM-4-
L, pGEM-4-N and pGEM-4-P/Cstop, respectively) have
been described [28,29].
Rescue of defective viruses
Eight hundred thousand BSR-T7/5 cells were seeded in a
35 mm Petri dish with DMEM10 medium. After 24 h, cells
were co-transfected with 7 μg of SVec/HA-M, SVec/HRSV/
FTM- or SVec/HMPV/FTM- plasmids, along with pGEM-L
(3.5  μg), pGEM-N (7 μg), and pGEM-P/Cstop (7 μg)
using the MBS mammalian transfection kit (Stratagene),
following the manufacturer's instructions. Twenty four
hours later the cells were infected with SeV in DMEM sup-
plemented with 2% FCS at a m.o.i. of 5, and after 24 h at
37°C the culture medium was harvested, clarified, and
kept at -80°C.
In parallel, rescue of the defective minigenome was
checked by immunofluorescence of BSR-T7/5 cells grow-
ing in microchamber slides. Transfection was done as
mentioned in the previous paragraph. Forty eight hours
after tranfection the cells were fixed and stained for
immunofluorescence with the following primary antibod-
ies: α-HA rabbit polyclonal antibody (Y-11, Santa Cruz
Biotechnology), α-HRSV F mouse monoclonal antibody
2F [30] or α-HMPV guinea pig polyclonal antibody (a
kind gift of A.D.M.E. Osterhaus, Rotterdam, The Nether-
lands). Secondary antibodies were fluorescein-linked α-
rabbit, α-mouse, or α-guinea pig immunoglobulin antis-
era (GE Healthcare).
Rescue of the minigenomes in eggs was achieved by inoc-
ulating 200 μl of culture supernatant of transfected/
infected BSR/T7-5 cells in the allantoic cavity of 9-day-old
embryonated eggs. The embryos were incubated at 34°C
for 48 h, and then transferred to 4°C. Allantoic fluid was
harvested after 16 h in the cold and clarified by low-speed
centrifugation. One hundred microliters of the allantoic
fluids were used for serial passages in embryonated eggs.
Allantoic fluids from the different passages were analyzed
by Western blot.
Western blot
Samples for protein analysis were subjected to 12% SDS-
PAGE and electrotransferred to PVDF membranes (Inmo-
bilon-P, Millipore). After blocking with I-Block agent
(Tropix), membranes were incubated with one of the fol-
lowing primary antibodies: α-chicken egg albumin mon-
oclonal antibody (C 6534, Sigma), α-HA high affinity rat
monoclonal antibody (3F10, Roche), α-Sendai F mono-
clonal antibody (GB5) or rabbit polyclonal antibodies
raised against synthetic peptides HRSV/F255–275 or HMPV/
F468–484 (numbers refer to amino acids included in the
peptides). After washing with 0,05%Tween-20 in PBS, the
membranes were incubated with horseradish peroxidase-
linked α-mouse, α-rat, or α-rabbit immunoglobulin sec-
ondary antibodies (GE Healthcare) and developed with
ECL.
Quantification of band intensities in Western blots of fig-
ure 2B was carried out using the Image J software [31].
Virus ultracentrifugation
Clarified allantoic fluids were centrifuged through a 25%
glycerol cushion in PBS at 35,000 rpm for 3 h at 4°C in a
SW40 rotor (Beckman). Pellets were then resuspended in
PBS, and analyzed by Western blot.
Site-directed mutagenesis
SVec/HRSV/FTM-NN was obtained by sequential mutagen-
esis of cleavage site II of HRSV/FTM- with the oligonucle-
otides F387-441+ (5'-
CCAATGTAACATTAAGCAACAACAACAACAACAACTT-
TCTTGGTTTTTTGTTAGG-3') and F441-387- (5'-
CCTAACAAAAAACCAAGAAAGTTGTTGTTGTTGTTGTT-





QuickChange Site-Directed Mutagenesis Kit (Stratagene)
following the manufacturer's instructions. The plasmid
obtained was checked by sequencing.
Protein purification and electron microscopy
HRSV/FTM-NN mutant was purified following procedures
used previously for purification of analogous mutants
from supernatants of Hep-2 cells infected with rVV [19].
Briefly, allantoic fluid was concentrated and buffer
exchanged to PBS by filtration through a 100 kDa pore
size membrane (Sartorius) and loaded onto an affinity
column made of the monoclonal antibody 2F [30] cova-
lently linked to Sepharose. Protein was eluted at low pH
and after neutralization loaded again onto a Superdex 200
10/300 GL (GE Healthcare) column. A homogeneous
peak eluted from the gel filtration column was collected
and purity checked by SDS-PAGE and Coomassie blue
staining. Purified HRSV/FTM-NN protein was absorbed
onto carbon films and stained with 1% sodium silico-
tungstate (pH 7.0). A Jeol 1200 electron microscope,BMC Biotechnology 2007, 7:17 http://www.biomedcentral.com/1472-6750/7/17
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operated at 100 kV, was used to view the samples. Micro-
graphs were taken under minimum-dose, accurate defo-
cus conditions to preserve details to ~1.5 nm[32].
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